The secondary research process involved comprehensive analysis of medical device regulatory databases, peer-reviewed orthopedic and neurosurgical journals, clinical trials registries, and authoritative healthcare organizations. Key sources included the US Food & Drug Administration (FDA) Center for Devices and Radiological Health (CDRH) 510(k) clearances, European Medicines Agency (EMA) medical device regulations, National Health Service (NHS) England device evaluations, Health Canada medical device licenses, and Pharmaceuticals and Medical Devices Agency (PMDA Japan).
Clinical and epidemiological data were sourced from the National Institutes of Health (NIH) and National Center for Biotechnology Information (NCBI/PubMed) for spinal fusion and motion preservation studies, Centers for Disease Control and Prevention (CDC) National Center for Health Statistics for spinal trauma and degenerative disease prevalence, World Health Organization (WHO) Global Burden of Disease Study for spinal disorder incidence, and OECD Health Statistics for surgical procedure volumes.
Professional society databases included the North American Spine Society (NASS), American Academy of Orthopaedic Surgeons (AAOS), Congress of Neurological Surgeons (CNS), Scoliosis Research Society (SRS), International Society for the Advancement of Spine Surgery (ISASS), and European Spine Journal. Additional sources comprised Eurostat healthcare expenditure data, Centers for Medicare & Medicaid Services (CMS) physician fee schedules and ICD-10 procedure codes (fusion: 0SG, disc replacement: 0SR), National Inpatient Sample (NIS) discharge data, and national ministry of health reports from Germany (Bundesministerium für Gesundheit), France (DREES), and Japan (MHLW). These sources provided regulatory approval pathways, clinical safety profiles, procedural volume trends, and reimbursement frameworks for thoracolumbar and cervical fixation systems, interbody fusion cages, artificial discs, vertebral compression fracture devices, and spinal biologics.